Erika Hamilton, Chair, Executive Committee Breast and Breast Program Lead at Sarah Cannon Research Institute, shared a post on LinkedIn:
“First trial to show a survival benefit in essentially a cisplatin-ineligible MIBC population
EFS HR 0.40 (almost double event free with EV pembro 24 mo)
OS HR 0.50 (16.6% at 24 mo)
pCR 8.6% vs. 57.1% w/ EV pembro.”
You can read also: Breast Cancer Advances at ESMO25 with Erika Hamilton
